|
Today's Headlines
Among the many poster sessions being presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL, are several on the latest trials that are planned to evaluate potential treatment options for breast cancer. These trials include 1 phase 2 study and 3 phase 3 studies.
» Study details
|
ADVERTISEMENT
Idiopathic Pulmonary Fibrosis (IPF)
IPF is the progressive formation of thick or scarred tissue in the lungs, resulting in loss of oxygen.
While there is currently no known cause, continued research seeks to find an answer,
alongside improved diagnosis and treatment options.
 Learn More
|
|
While the high cost of Gilead Science's Harvoni—as well as other hepatitis C drugs—has received criticism from patients, managed care organizations, lawmakers and others, there is some positive news about the drug.
» Read more
|
Continuing Education
This month's CE activity is part of the CE series, MTM for the Patient with Respiratory Disease. From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.
The goal of this month's activity is to review the stepwise approach to the management of pediatric and adult asthma and the pharmacotherapies commonly used in asthma treatment.
To read and print the article with TEST questions, click here.
To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the Session Code: 15DT30-PYJ23.
Announcement: The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php. All current user registration has been uploaded for your convenience. Current users do not need to register. To review you registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/
|
|
EDITOR'S PICK
In patients with moderate-to-severe chronic obstructive pulmonary disease (COPD), investigational indacaterol/glycopyrronium (QVA149) bromide significantly improved lung function compared to the single bronchodilators, according to data presented at the American Thoracic Society (ATS) International Conference. » Key goal of COPD therapy
|
|
|
Like
Tweet
